Overview

A Study to See the Effect of NNC0194-0499 Alone or in Combination With Semaglutide on Blood Sugar Control in People Living With Type 1 Diabetes

Status:
RECRUITING

Trial end date:
2026-09-25

Target enrollment:

Participant gender:

Summary

This study is testing the effect of a new study medicine NNC0194-0499 in type 1 diabetes. The purpose of the study is to compare the effect of NNC0194-0499 on the blood sugar levels of participants with type 1 diabetes when taken in combination with semaglutide or placebo. All participants will receive standard of care insulin treatment. The study will last for about 36 weeks.

Phase:

PHASE1

Details

Lead Sponsor:

Novo Nordisk A/S

Treatments:

semaglutide